+ 1-971-202-1575 , TollFree:+ 1-800-910-6452
  [email protected]
WEX Pharmaceuticals Inc. - Strategic SWOT Analysis Review
  • Published : January , 2014
  • |
  • Number of Pages : 20
  • |
  • Published By : GlobalData



Report Overview
WEX Pharmaceuticals Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

WEX Pharmaceuticals Inc. (WEX) is a pharmaceutical company. The company carries out the discovery, development, manufacture and commercialization of new class therapeutics for the treatment of acute and chronic pain. The company's products are based on Tetrodotoxin (TTX), a sodium channel blocker. The clinical trial program of the company includes TEC-006 and TTX-CINP-201. TEC-006 is being studied for the treatment of moderate to severe cancer related pain and TTX-CINP-201 is being developed for moderate to severe neuropathic pain caused by chemotherapy in patients with cancer. It is a subsidiary of CK Life Sciences Int'l., (Holdings) Inc.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.



Similar Market Studies

PUBLISHED REPORTS


UPCOMING REPORTS


Reports and Intelligence


We Accept

  • Stay Connected

Copyright ©2017 Reportsandintelligence All Rights Reserved